Stay updated with breaking news from Pascal Prigent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim...
US Food and Drug Administration has granted Priority Review for New Drug Application for elafibranor in PBC, and European Medicine Agency has also validated the Marketing Authorization Application ...
Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the
Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in...
Agreement gives Ipsen global1 rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis ...